Advertisement

Erectile Dysfunction

  • Karthik Gunasekaran
  • Shah Dupesh Khan
Chapter

Abstract

Erectile dysfunction (ED) is the most well publicized among all the causes of male sexual dysfunction. ED has been frequently defined as the inability to sustain or maintain an erectile function that is sufficient enough to achieve sexual intercourse that is satisfactory leading to considerable distress to one or both partners [1]. The consistency of the problem is more important since the sexual dysfunction should have been present for at least a period of 3 months before a conclusive diagnosis is made [2].

References

  1. 1.
    NIH Consensus Development Panel on Impotence. Impotence: NIH consensus development panel on impotence. JAMA. 1993;270(1):83–90.CrossRefGoogle Scholar
  2. 2.
    Lue TF, Giuliano F, Montorsi F, Rosen RC, Andersson KE, Althof S, Christ G, Hatzichristou D, Hirsch M, Kimoto Y, Lewis R. Summary of the recommendations on sexual dysfunctions in men. J Sex Med. 2004;1(1):6–23.CrossRefGoogle Scholar
  3. 3.
    Aytac IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999;84:50–6.CrossRefGoogle Scholar
  4. 4.
    Inman BA, Sauver JL, Jacobson DJ, McGree ME, Nehra A, Lieber MM, et al. A population-based, longitudinall study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc. 2009;84(2):108–13.CrossRefGoogle Scholar
  5. 5.
    Feldman HA, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol. 1994;151:54.CrossRefGoogle Scholar
  6. 6.
    Fugl-Meyer AR, Lodnert G, Branholm IB, Fugl-Meyer KS. On life satisfaction in male erectile dysfunction. Int J Impot Res. 1997;9:141–8.CrossRefGoogle Scholar
  7. 7.
    Dong JY, Chang YH, Win Q. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol. 2011;58(13):1378–85.CrossRefGoogle Scholar
  8. 8.
    Baldwin K, Ginsberg P, Harkaway RC. Under-reporting of erectile dysfunction among men with unrelated urologic conditions. Int J Impot Res. 2003;15(2):87–9.CrossRefGoogle Scholar
  9. 9.
    Koldny RC, Kahn CB, Goldstein HH, Barnett DM. Sexual function in diabetic men. Diabetes. 1973;23:306–9.CrossRefGoogle Scholar
  10. 10.
    McCulloch DK, Campbell IW, Wu FC, Prescott RJ, Clarke BF. The prevalence of diabetic impotence. Diabetologia. 1980;18:279–83.CrossRefGoogle Scholar
  11. 11.
    McCulloch DK, Young RJ, Prescott RJ, Campbell IW, Clarke BF. The natural history of impotence in diabetic men. Diabetologia. 1984;26:437–40.CrossRefGoogle Scholar
  12. 12.
    Dunsmuir WD, Holmes SAV. The aetiology and management of erectile, ejaculatory and fertility problems in men with diabetes mellitus. Diabet Med. 1996;13:700–8.CrossRefGoogle Scholar
  13. 13.
    Sáenz de Tejada I, Angulo J, Cellek S, González-Cadavid N, Heaton J, Pickard R, Simonsen U. Physiology of erectile function. J Sex Med. 2004;1(3):254–65.CrossRefGoogle Scholar
  14. 14.
    Mullarkey CJ, Edelstein D, Brownlee M. Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun. 1990;173:932–9.CrossRefGoogle Scholar
  15. 15.
    Angulo J, Sanchez-Ferrer CF, Peiro C, Marin J, Rodriguez Mañas L. Impairment of endothelium- dependent relaxation by increasing percentages of glycosylated human hemoglobin. Possible mechanisms involved. Hypertension. 1996;28:583–92.CrossRefGoogle Scholar
  16. 16.
    Pieper GM, Dondlinger LA. Plasma and vascular tissue arginine are decreased in diabetes: acute arginine supplementation restores endothelium dependent relaxation by augmenting cGMP production. J Pharmacol Exp Ther. 1997;283:684–91.PubMedGoogle Scholar
  17. 17.
    Bivalacqua TJ, Hellstrom WJG, Kadowitz PJ, Champion HC. Increased expression of arginase II in human diabetic corpus cavernosum: in diabetic associated erectile dysfunction. Biochem Biophys Res Commun. 2001;283:923–7.CrossRefGoogle Scholar
  18. 18.
    Jackson G. Sexual dysfunction and diabetes. Int J Clin Pract. 2004;58(4):358–62.CrossRefGoogle Scholar
  19. 19.
    Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil diabetes study group. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. JAMA. 1999;281(5):421–6.CrossRefGoogle Scholar
  20. 20.
    Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease. Lancet. 2008;371:1513–8.CrossRefGoogle Scholar
  21. 21.
    Manolis A, Doumas M. Sexual dysfunction: the ‘prima ballerina’ of hypertension-related quality-of-life complications. J Hypertens. 2008;26:2074–84.CrossRefGoogle Scholar
  22. 22.
    Doumas M, Douma S. Sexual dysfunction in essential hypertension: myth or reality? J Clin Hypertens. 2006;8:269–74.CrossRefGoogle Scholar
  23. 23.
    Doumas M, Boutari C, Viigimaa M. Arterial hypertension and erectile dysfunction: an under-recognized duo. J Cardiol Pract. 2016;14(4):1–7.Google Scholar
  24. 24.
    Sharp RP, Gales BJ. Nebivolol versus other beta blockers in patients with hypertension and erectile dysfunction. Ther Adv Urol. 2017;9(2):59–63.CrossRefGoogle Scholar
  25. 25.
    Chang HH, Chien CT, Hsu SP. The exploration of pathophysiologic mechanisms and therapeutic strategy for diabetes and hypertension related erectile dysfunction. Obes Rev. 2016;17:42.CrossRefGoogle Scholar
  26. 26.
    Skeldon SC, Detsky AS, Goldenberg SL, Law MR. Erectile dysfunction and undiagnosed diabetes, hypertension, and hypercholesterolemia. Ann Fam Med. 2015;13(4):331–5.CrossRefGoogle Scholar
  27. 27.
    Krane RJ, Goldstein I, Saenz de Tejada I. Impotence. N Engl J Med. 1989;321:1648–59.CrossRefGoogle Scholar
  28. 28.
    Feldman HA, Goldstein I, Hatzchristou DG, Krane RJ, McKinlay JB. Impotence and its medical and social correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54–61.CrossRefGoogle Scholar
  29. 29.
    Azadzoi KM, Goldstein I, Siroky MB, Traish AM, Krane RJ, Saenz de Tejada I. Mechanisms of ischemia-induced cavernosal smooth muscle relaxation in a rabbit model of vasculogenic erectile dysfunction. J Urol. 1998;160:2216–22.CrossRefGoogle Scholar
  30. 30.
    Azadzoi KM, Saenz de Tejada I. Hypercholesterolemia impairs endothelium-dependent relaxation of rabbit corpus cavernosum smooth muscle. J Urol. 1991;146:238–40.CrossRefGoogle Scholar
  31. 31.
    Elgendy AY, Elgendy IY, Mahmoud AN, Al-Ani M, Moussa M, Mahmoud A, Mojadidi MK, Anderson RD. Statin use in men and new onset of erectile dysfunction: a systematic review and meta-analysis. Am J Med. 2017;131(4):387–94.CrossRefGoogle Scholar
  32. 32.
    Hodges LD, Kirby M, Solanki J, O’Donnell J, Brodie DA. The temporal relationship between erectile dysfunction and cardiovascular disease. Int J Clin Pract. 2007;61(12):2019–25.CrossRefGoogle Scholar
  33. 33.
    Gupta BP, Murad MH, Clifton MM, Prokop L, Nehra A, Kopecky SL. The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med. 2011;171(20):1797–803.CrossRefGoogle Scholar
  34. 34.
    Greenstein A, Chen J, Miller H, Matzkin H, Villa Y, Braf Z. Does severity of ischemic coronary disease correlate with erectile function? Int J Impot Res. 1997;9(3):123–6.CrossRefGoogle Scholar
  35. 35.
    Nehra A, Jackson G, Miner M, Billups KL, Burnett AL, Buvat J, Carson CC, Cunningham GR, Ganz P, Goldstein I, Guay AT. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012;87(8):766–78.CrossRefGoogle Scholar
  36. 36.
    Qaseem A, Snow V, Denberg TD, et al. Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American college of physicians. Ann Intern Med. 2009;151(9):639–49.CrossRefGoogle Scholar
  37. 37.
    Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536–59.CrossRefGoogle Scholar
  38. 38.
    Buvat J, Bou JG. Significance of hypogonadism in erectile dysfunction. World J Urol. 2006;24(6):657–67.CrossRefGoogle Scholar
  39. 39.
    Blute M, Hakimian P, Kashanian J, Shteynshluyger A, Lee M, Shabsigh R. Erectile dysfunction and testosterone deficiency. Front Horm Res. 2009;37:108–22.CrossRefGoogle Scholar
  40. 40.
    Thompson PD, Buchner D, Pina IL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, physical activity, and metabolism (Subcommittee on Physical activity). Circulation. 2003;107(24):3109–16.CrossRefGoogle Scholar
  41. 41.
    Netz Y, Wu MJ, Becker BJ, Tenenbaum G. Physical activity and psychological well-being in advanced age: a meta-analysis of intervention studies. Psychol Aging. 2005;20(2):272–84.CrossRefGoogle Scholar
  42. 42.
    Bassuk SS, Manson JE. Epidemiological evidence for the role of physical activity in reducing risk of type 2 diabetes and cardiovascular disease. J Appl Physiol. 2005;99(3):1193–204.CrossRefGoogle Scholar
  43. 43.
    Hatzimouratidis K, Amar E, Eardley I, F. Giuliano, I. Moncada, A. Salonia. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. European Association of Urology website. http://uroweb.org/guideline/male-sexual-dysfunction/. Updated 2015. Eur Urol 2015;68(4):e78.
  44. 44.
    Rosen RC, Cappelleri JC, Gendrano Iii N. The international index of erectile function (IIEF): a state-of-the-science review. Int J Impot Res. 2002;14(4):226.CrossRefGoogle Scholar
  45. 45.
    O’Leary MP, Fowler FJ, Lenderking WR, Barber B, Sagnier PP, Guess HA, Barry MJ. A brief male sexual function inventory for urology. Urology. 1995;46(5):697–706.CrossRefGoogle Scholar
  46. 46.
    Cappelleri JC, Rosen RC. The sexual health inventory for men (SHIM): a 5-year review of research and clinical experience. Int J Impot Res. 2005;17(4):307.CrossRefGoogle Scholar
  47. 47.
    Montague DK, Jarow JP, Broderick GA, et al. For the erectile dysfunction guideline update panel. Chapter 1: the management of erectile dysfunction: an AUA update. J Urol. 2005;174(1):230–9.CrossRefGoogle Scholar
  48. 48.
    Erectile Dysfunction Guideline Update Panel. The management of erectile dysfunction: an update. Baltimore, MD.: American Urological Association Education And Research, Inc.; 2005. http://www.ngc.gov/summary/summary.aspx?doc_id=10018&nbr=005332&string=erectile+AND+dysfunction. Accessed 9 July 2008.
  49. 49.
    Jardin A, Wagner G, Khoury S, et al. Recommendations of the 1st International. Consultation on Erectile Dysfunction. In: Jardin A, Wagner G, Khoury S, et al., editors. Erectile dysfunction. Plymouth: Health Publication Ltd; 2000. p. 711–26.Google Scholar
  50. 50.
    Esposito K, Giugliano F, Di Palo C, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA. 2004;291(24):2978–84.CrossRefGoogle Scholar
  51. 51.
    Kostis JB, Jackson G, Rosen R, et al. Sexual dysfunction and cardiac risk (the second Princeton consensus conference). Am J Cardiol. 2005;96(2):313–21.CrossRefGoogle Scholar
  52. 52.
    Rudd RM, Gellert AR, Studdy PR, Geddes DM. Inhibition of exercise-induced asthma by an orally absorbed mast cell stabilizer (M & B 22,948). Br J Dis Chest. 1983;77(1):78–86.CrossRefGoogle Scholar
  53. 53.
    FDA approves oral therapy for erectile dysfunction. Am J Health Syst Pharm 1998;55(10):981, 984.Google Scholar
  54. 54.
    Carson CC, Burnett AL, Levine LA, Nehra A. The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology. 2002;60(2 Suppl 2):12–27.CrossRefGoogle Scholar
  55. 55.
    Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol. 2002;53(Suppl 1):5S–12S.CrossRefGoogle Scholar
  56. 56.
    Montorsi F, Verheyden B, Meuleman E, et al. Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol 2004; 45(3):339-344; discussion 344-5.CrossRefGoogle Scholar
  57. 57.
    Porst H, Padma-Nathan H, Giuliano F, et al. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology. 2003;62(1):121–5; discussion 125-6CrossRefGoogle Scholar
  58. 58.
    Doumas M, Lazaridis A, Katsiki N, Athyros V. PDE-5 inhibitors: clinical points. Curr Drug Targets. 2015;16(5):420–6.CrossRefGoogle Scholar
  59. 59.
    Gresser U, Gleiter CH. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil-review of the literature. Eur J Med Res. 2002;7(10):435–46.PubMedGoogle Scholar
  60. 60.
    Thurtell MJ, Tomsak RL. Nonarteritic anterior ischemic optic neuropathy with PDE-5 inhibitors for erectile dysfunction. Int J Impot Res. 2008;20(6):537–43.CrossRefGoogle Scholar
  61. 61.
    Azzouni F, Abu samra K. Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature. J Sex Med. 2011;8(10):2894–903.CrossRefGoogle Scholar
  62. 62.
    Jannini EA, Isidori AM, Gravina GL, Endotrial study Group, et al. The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction. J Sex Med. 2009;6(9):2547–60.CrossRefGoogle Scholar
  63. 63.
    von Keitz A, Rajfer J, Segal S, et al. A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. Eur Urol 2004; 45(4): 499-507; discussion 507-9.Google Scholar
  64. 64.
    Govier F, Potempa AJ, Kaufman J, Denne J, Kovalenko P, Ahuja S. A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction. Clin Ther. 2003;69(11):2709–23.CrossRefGoogle Scholar
  65. 65.
    Porst H, Rajfer J, Casabé A, Feldman R, Ralph D, Vieiralves LF, Esler A, Wolka AM, Klise SR. Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. J Sex Med. 2008;5(9):2160–9.CrossRefGoogle Scholar
  66. 66.
    Heidelbaugh JJ. Management of erectile dysfunction. Am Fam Physician. 2010;81(3):305–12.PubMedGoogle Scholar
  67. 67.
    Lewis RW, Witherington R. External vacuum therapy for erectile dysfunction: use and results. World J Urol. 1997;15(1):78–82.CrossRefGoogle Scholar
  68. 68.
    Carson CC, Mulcahy JJ, Govier FE. Efficacy, safety and patient satisfaction outcomes of the AMS 700CX inflatable penile prosthesis: results of a long-term multicenter study. J Urol. 2000;164(2):376–80.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Karthik Gunasekaran
    • 1
  • Shah Dupesh Khan
    • 1
  1. 1.The Metromale Clinic and Fertility CenterChennaiIndia

Personalised recommendations